QASI®-COVID19 (Quality Assessment and Standardization of Indicators relevant to COVID-19)<<Return to Laboratory
To support and maintain the success of rapid diagnostics for SARS-CoV-2, QASI-COVID19, an external quality assessment (EQA) scheme for the Xpert® Xpress SARS-CoV-2 Assay was launched in July 2020. This program is based on the NML’s longstanding international EQA program for HIV rapid diagnostics, known worldwide by its trademark name, QASI® (Quality Assessment and Standardization of Indicators).
The QASI program, managed and operated by the National HIV and Retrovirology Laboratory at the JC Wilt Infectious Diseases Research Centre in Winnipeg, Canada, has been providing quality assessment programming for HIV for over 20 years. The new QASI-COVID19 EQA scheme will offer similar services for sites performing rapid SARS-CoV-2 detection in Canada.
QASI-COVID19 provides extensive feedback in the form of assessment reports and direct dialogue to address non-conformances and provide corrective and preventative action recommendations intended to create sustainable quality testing standards for participants.
Frequency of distribution: The QASI-COVID19 scheme will consist of a 4-specimen proficiency-testing panel administered six times a year
To ensure and maintain quality testing practices for SARS CoV-2 detection at POC testing sites in Canada utilizing the Xpert® Xpress SARS-CoV-2 Assay.
There is no fee to enrol or participate in the QASI-COVID19 program.
Eligible participants are POC sites actively performing testing for SARS-CoV-2 using the Xpert® Xpress SARS-CoV-2 Assay on the GeneXpert® system.
Confidentiality of testing results and performance is maintained using a password protected online database and numerical IDs to distinguish testing sites.
Please contact email@example.com to apply for any of our EQA programs.